Press Releases April 15, 2026 08:00 PM

PacBio to Report First Quarter 2026 Financial Results on May 7, 2026

PacBio schedules Q1 2026 earnings call for May 7, 2026

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
PACB

PacBio announced it will report its first quarter 2026 financial results on May 7, 2026, and hold a conference call webcast to discuss the results. The company specializes in advanced sequencing solutions for life science research applications.

PacBio to Report First Quarter 2026 Financial Results on May 7, 2026
PACB
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • PacBio will release Q1 2026 financial results on May 7, 2026.
  • Conference call and webcast will discuss the quarterly performance.
  • Company focuses on advanced sequencing technology for research including human genomics, plant and animal sciences, infectious diseases, and oncology.

MENLO PARK, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2026 financial results on Thursday, May 7, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

The call will be webcast and may be accessed on PacBio’s website at https://investor.pacificbiosciences.com/.

Date: Thursday, May 7, 2026, at 4:30 p.m. ET (1:30 p.m. PT)
Listen live via internet or replay: https://investor.pacificbiosciences.com/
Toll-free: 1-888-349-0136
International: 1-412-317-0459

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Contacts

Investors:
[email protected]

Media:
[email protected]


Risks

  • Financial results may not meet investor expectations, causing stock volatility.
  • Research use only products limit market to non-diagnostic applications, restricting potential revenue growth.
  • Dependence on continued demand within scientific research sectors, which can be influenced by funding and economic conditions.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026